Delivery Order SPE2DB22D3401-SPE2DB25FT6KV
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,666.64 to AmerisourceBergen Drug Corp for Forteo 560 mcg/2.24 mL pen injections on September 19, 2025, with an ultimate completion date of September 22, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Forteo is a bone-building medication used to treat osteoporosis in patients at high risk of...
- The Defense Logistics Agency awarded a $13,965.22 delivery order to AmerisourceBergen Drug Corp for Forteo (560 mcg/2.24 mL pen injections) on June 18, 2025, with an ultimate completion date of June 20, 2025. This firm fixed-price contract, which was competitively awarded with no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical. The contract will be performed at the company's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $2,601.43 to AmerisourceBergen Drug Corp for Forteo (560 mcg/2.24 mL pen injections) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $22,105.54 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Forteo (560 mcg/2.24 mL pen injections). This contract represents a firm fixed price delivery order with an ultimate completion date of August 12, 2025, and is being performed at the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was utilized for this competitive award. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $2,749.98 delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Forteo (teriparatide) 560 mcg/2.24 mL pen injections. This firm fixed-price, non-set-aside contract is classified as a delivery order with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Forteo is a pharmaceutical product used to treat osteoporosis and bone-related...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,575.97 to AmerisourceBergen Drug Corp for the supply of Forteo 560 mcg/2.24 mL pen injections (2.24 mL units). This firm fixed-price contract, awarded on June 25, 2025, with an ultimate completion date of June 26, 2025, was competitively awarded with no set-aside designation. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Forteo is a FDA-approved medication used to treat...
- The Defense Logistics Agency awarded a delivery order valued at $1,833.32 to AmerisourceBergen Drug Corp for Forteo (560 mcg/2.24 ml pen injections) on September 7, 2025, with completion scheduled for September 8, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. Forteo is a prescription medication used to treat osteoporosis and increase bone mass in patients at risk...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Forteo 560 MCG/2.24 ML pen injections valued at $7,333.28. This is a firm fixed price delivery order with an ultimate completion date of September 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award was not made under any small business set-aside program and was competitively awarded. Forteo is a prescription...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,125.19 on September 12, 2025, with completion scheduled for September 15, 2025. The order covers Forteo 560 mcg/2.24 mL pen injections, a brand-name pharmaceutical product used in osteoporosis treatment. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition to AmerisourceBergen's Corporate Office division located in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a $54,040.80 delivery order to AmerisourceBergen Drug Corp for Forteo (560 mcg/2.24 ml pen injections), a pharmaceutical product used to treat osteoporosis. The contract is a firm fixed price delivery order with no set-aside designation, issued on July 31, 2025, with an ultimate completion date of August 1, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT6KVDelivery Order
The Defense Logistics Agency awarded a $3,666.64 delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Forteo (560 mcg/2.24 mL pen injections). This is a firm fixed price, non-set-aside contract with a completion date of September 24, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Forteo is a prescription medication used to treat osteoporosis and increase bone density, and this order represents a typical pharmaceutical delivery under AmerisourceBergen's extensive federal contract portfolio. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen serves military and veteran healthcare systems through this comprehensive global pharmaceutical support vehicle. The company's contract awards with DLA demonstrate its capability to supply a wide range of pharmaceutical products across multiple therapeutic domains through competitive, firm fixed price arrangements, supporting the Defense Health Agency and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 9/23/25 |